- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
SynergEyes awarded sixth U.S. patent
SynergEyes Inc. has been awarded its sixth U.S. patent. The new patent is for improving the hydrophilicity-long-term comfort and wettability-of hybrid contact lenses, according to the company.
Carlsbad, CA-SynergEyes Inc. has been awarded its sixth U.S. patent. The new patent is for improving the hydrophilicity-long-term comfort and wettability-of hybrid contact lenses, according to the company.
SynergEyes co-founder and Vice President of Manufacturing Joe Collins commented, "This patent enhances our intellectual property portfolio and represents highly valued strategic assets that distinguish our products in the contact lens industry."
SynergEyes' other patents are for its signature high-Dk hybrid contact lens, the HyperBond technology that provides the strong junction between the rigid center and soft skirt, and the method used to provide a rotationally stable platform for front surface toric, de-centered multifocal, and wavefront-guided hybrid lenses.
